TernaryTx is a biotechnology company developing an AI- and physics-driven platform to prospectively design small-molecule molecular glue therapeutics
TernaryTx is a biotechnology company developing an AI- and physics-driven platform to prospectively design small-molecule molecular glue therapeutics. Its platform assesses target glueability, predicts protein complexes, evaluates complex stability, and optimizes glue compounds. The company works across disease areas and modalities, with programs including degraders for immunology and neurodegenerative disease and next-generation RIPTAC-like GRIPs for oncology.